Department of Pharmacy Practice and Science, University of Arizona R. Ken Coit College of Pharmacy, Tucson, AZ, USA.
Regional University Hospital Centre Tours, Department of Hemostasis, Tours, France; University of Tours, EA4245, T2i, Tours, France.
Thromb Res. 2023 Sep;229:198-208. doi: 10.1016/j.thromres.2023.07.011. Epub 2023 Jul 20.
Heparin-induced thrombocytopenia (HIT) is an antibody-mediated immune response against platelet factor 4 (PF4) bound to heparin anticoagulants. A priori identification of patients at-risk for HIT remains elusive and a number of risk factors have been identified, but these associations and their effect sizes have limited validation in large cohorts of suspected HIT patients. The aim of this study was to investigate existing anti-PF4/heparin antibody thresholds and model the relationship of demographic variables and anti-PF4/heparin antibody levels with functional assay positivity across multiple institutions in the absence of detailed clinical data. In a large collection of suspected HIT patients (n = 8904), we tested for associations between laboratory and demographic variables and functional assay positive status as well as anti-PF4/heparin antibody levels. We also tested for correlation between IgG-specific and polyspecific (IgG/IgA/IgM) anti-PF4/heparin antibody values and their ability to predict functional assay positive status using area under the receiver operating characteristic (AUROC). Logistic regression identified increasing anti-PF4/heparin antibody OD levels (OR = 51.84 [37.27-74.34], p < 2.0 × 10) and female sex (OR = 1.47 [1.19-1.82], p = 3.5 × 10) as risk factors for positive functional assay in the largest cohort with consistent effect sizes in two other cohorts. In a subset of 1175 patients, polyspecific and IgG-specific anti-PF4/heparin antibody values were heterogeneous (mean coefficient of variation = 31.9 %), but strongly correlated (rho = 0.878; p < 2 × 10) with similar prediction of functional assay positivity (polyspecific AUROC = 0.976 and IgG-specific AUROC = 0.980). Thus, we recapitulate previously identified risk factors of functional assay positivity, providing precise effect sizes in a large observational population of suspected HIT patients. Our data reinforce the necessity of functional assay confirmation and suggest that, despite heterogeneity, polyspecific and IgG-specific anti-PF4/heparin antibody assays predict functional assay positive status similarly, even in the absence of 4Ts scores and detailed clinical data.
肝素诱导的血小板减少症(HIT)是一种针对血小板因子 4(PF4)与肝素抗凝剂结合的抗体介导的免疫反应。预先识别 HIT 高危患者仍然难以实现,已经确定了许多危险因素,但这些关联及其效应大小在大量疑似 HIT 患者的大队列中验证有限。本研究的目的是在缺乏详细临床数据的情况下,在多个机构中调查现有的抗 PF4/肝素抗体阈值,并研究人口统计学变量与抗 PF4/肝素抗体水平与功能测定阳性之间的关系。在大量疑似 HIT 患者(n=8904)中,我们测试了实验室和人口统计学变量与功能测定阳性状态以及抗 PF4/肝素抗体水平之间的关联。我们还测试了 IgG 特异性和多特异性(IgG/IgA/IgM)抗 PF4/肝素抗体值之间的相关性及其使用接收器操作特征(AUROC)曲线下面积(AUC)预测功能测定阳性状态的能力。逻辑回归确定了抗 PF4/肝素抗体 OD 值的增加(OR=51.84[37.27-74.34],p<2.0×10)和女性性别(OR=1.47[1.19-1.82],p=3.5×10)是最大队列中功能测定阳性的危险因素,在另外两个队列中具有一致的效应大小。在 1175 名患者的亚组中,多特异性和 IgG 特异性抗 PF4/肝素抗体值存在异质性(平均变异系数=31.9%),但具有很强的相关性(rho=0.878;p<2×10),对功能测定阳性的预测相似(多特异性 AUROC=0.976 和 IgG 特异性 AUROC=0.980)。因此,我们重现了先前确定的功能测定阳性的危险因素,在一个大型疑似 HIT 患者观察性人群中提供了精确的效应大小。我们的数据强化了对功能测定确认的必要性,并表明,尽管存在异质性,多特异性和 IgG 特异性抗 PF4/肝素抗体测定对功能测定阳性状态的预测相似,即使在缺乏 4Ts 评分和详细临床数据的情况下也是如此。